This review article examines the role of orthobiologics, specifically platelet-rich plasma (PRP), mesenchymal stem cells (MSCs) and bone morphogenetic protein (BMP), in bone healing and the treatment of joint and tendon degeneration in the upper limb. The historical development, theorized mechanisms and clinical applications of these orthobiologics are explored, focussing on their effectiveness in fracture non-unions, osteoarthritis and tendinopathies. The evidence for bone healing shows promising results, particularly for MSCs and BMP in the treatment of non-unions. However, despite preclinical evidence of regenerative abilities of PRP and MSCs, the clinical trials do not support their use for tendinopathies or osteoarthritis. Before widespread clinical application of PRP or MSCs for upper limb degenerative conditions, their efficacy needs to be established through large, high-quality trials.
Abdelsabor SabaahHMEl FattahRAAl ZifzafDSaadH.A comparative study for different types of thumb base osteoarthritis injections: a randomized controlled interventional study. Orthop Traumatol Rehabil. 2020,
22: 447–54.
2.
Acosta-OlivoCGarza-BorjonASimental-MendiaMVilchez-CavazosFTamez-MataYPeña-MartinezV.Delayed union of humeral shaft fractures: comparison of autograft with and without platelet-rich plasma treatment: a randomized, single blinded clinical trial. Arch Orthop Trauma Surg. 2017,
137: 1247–52.
3.
AlbarenqueSMZwackaRMMohrA.Both human and mouse mesenchymal stem cells promote breast cancer metastasis. Stem Cell Res. 2011,
7: 163–71.
4.
Arthur VithranDTXieWOpokuMEssienAEHeMLiY.The efficacy of platelet-rich plasma injection therapy in the treatment of patients with achilles tendinopathy: a systematic review and meta-analysis. J Clin Med. 2023,
12: 995.
5.
AspinenSNordbackPHAnttilaTStjernberg-SalmelaSRyhänenJKosolaJ.Platelet-rich plasma versus corticosteroid injection for treatment of trigger finger: study protocol for a prospective randomized triple-blind placebo-controlled trial. Trials. 2020,
21: 984.
6.
BadlaniNInoueAHealeyRCouttsRAmielD.The protective effect of OP-1 on articular cartilage in the development of osteoarthritis. Osteoarthritis Cartilage. 2008,
16: 600–6.
7.
BadlaniNOshimaYHealeyRCouttsRAmielD.Use of bone morphogenic protein-7 as a treatment for osteoarthritis. Clin Orthop Relat Res. 2009,
467: 3221–9.
8.
BajadaSHarrisonPEAshtonBACassar-PullicinoVNAshammakhiNRichardsonJB.Successful treatment of refractory tibial nonunion using calcium sulphate and bone marrow stromal cell implantation. J Bone Joint Surg Br. 2007,
89: 1382–6.
9.
Baksh N, Hannon CP, Murawski CD, Smyth NA, Kennedy JG. Platelet-rich plasma in tendon models: a systematic review of basic science literature. Arthroscopy. 2013, 29: 596–607.
10.
BaltzerAWAMoserCJansenSAKrauspeR.Autologous conditioned serum (Orthokine) is an effective treatment for knee osteoarthritis. Osteoarthritis Cartilage. 2009,
17: 152–60.
11.
BarmanASinhaMKSahooJ, et al.
Platelet-rich plasma injection in the treatment of patellar tendinopathy: a systematic review and meta-analysis. Knee Surg Relat Res. 2022,
34: 22.
12.
BennellKLPatersonKLMetcalfBR, et al.
Effect of intra-articular platelet-rich plasma vs placebo injection on pain and medial tibial cartilage volume in patients with knee osteoarthritis: the RESTORE randomized clinical trial. JAMA. 2021,
326: 2021–30.
13.
Bilic R, Simic P, Jelic M, Stern-Padovan R, Dodig D, Pompe van Meerdervoort H, Martinovic S, Ivankovic D, Pecina M, Vukicevic S. Osteogenic protein-1 (BMP-7) accelerates healing of scaphoid non-union with proximal pole sclerosis. International Orthopaedics. 2006, 30: 128–34.
14.
CaloriGMTagliabueLGalaLd’ImporzanoMPerettiGAlbisettiW.Application of rhBMP-7 and platelet-rich plasma in the treatment of long bone non-unions: a prospective randomised clinical study on 120 patients. Injury. 2008,
39: 1391–402.
15.
CamargoPMLekovicVWeinlaenderMVasilicNMadzarevicMKenneyEB.Platelet-rich plasma and bovine porous bone mineral combined with guided tissue regeneration in the treatment of intrabony defects in humans. J Periodontal Res. 2002,
37: 300–6.
CarreiraACOZambuzziWFRossiMCAstorino FilhoRSogayarMCGranjeiroJM.Bone morphogenetic proteins: promising molecules for bone healing, bioengineering, and regenerative medicine. Vitam Horm. 2015,
99: 293–322.
18.
CateriniRPotenzaVIppolitoEFarsettiP.Treatment of recalcitrant atrophic non-union of the humeral shaft with BMP-7, autologous bone graft and hydroxyapatite pellets. Injury. 2016,
47 Suppl 4: S71–7.
19.
CentenoCJAl-SayeghHFreemanMDSmithJMurrellWDBubnovR.A multi-center analysis of adverse events among two thousand, three hundred and seventy two adult patients undergoing adult autologous stem cell therapy for orthopaedic conditions. Int Orthop. 2016,
40: 1755–65.
20.
ChaverriDGallardo-VillaresSPintoJA, et al.
Treatment of non-hypertrophic pseudoarthrosis of long bones with a Tissue Engineered Product loaded with autologous bone marrow-derived mesenchymal stromal cells: results from a phase IIa, prospective, randomized, parallel, pilot clinical trial comparing to iliac crest autograft. Injury. 2024,
55: 111596.
21.
ChuJDuanWYuZ, et al.
Intra-articular injections of platelet-rich plasma decrease pain and improve functional outcomes than sham saline in patients with knee osteoarthritis. Knee Surg Sports Traumatol Arthrosc. 2022,
30: 4063–71.
22.
ChunS-WKimWLeeSY, et al.
A randomized controlled trial of stem cell injection for tendon tear. Sci Rep. 2022,
12: 818.
23.
ConnollyJFGuseRTiedemanJDehneR.Autologous marrow injection as a substitute for operative grafting of tibial nonunions. Clin Orthop Relat Res. 1991: 259–70.
24.
ConwayJDShabtaiLBauernschubASpechtSC.BMP-7 versus BMP-2 for the treatment of long bone nonunion. Orthopedics. 2014,
37: e1049–57.
25.
CotterEJWangKCYankeABChubinskayaS.Bone marrow aspirate concentrate for cartilage defects of the knee: from bench to bedside evidence. Cartilage. 2018,
9: 161–70.
26.
DavatchiFAbdollahiBSMohyeddinMShahramFNikbinB.Mesenchymal stem cell therapy for knee osteoarthritis. Preliminary report of four patients. Int J Rheum Dis. 2011,
14: 211–5.
27.
De FrancescoFGravinaPBusatoA, et al.
Stem cells in autologous microfragmented adipose tissue: current perspectives in osteoarthritis disease. Int J Mol Sci. 2021,
22: 10197.
28.
Di NicolaMCarlo-StellaCMagniM, et al.
Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002,
99: 3838–43.
29.
DingD-CChangY-HShyuW-CLinS-Z.Human umbilical cord mesenchymal stem cells: a new era for stem cell therapy. Cell Transplant. 2015,
24: 339–47.
30.
Dohan EhrenfestDMRasmussonLAlbrektssonT.Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol. 2009,
27: 158–67.
31.
DonovanRLEdwardsTAJudgeABlomAWKunutsorSKWhitehouseMR.Effects of recurrent intra-articular corticosteroid injections for osteoarthritis at 3 months and beyond: a systematic review and meta-analysis in comparison to other injectables. Osteoarthritis Cartilage. 2022,
30: 1658–69.
32.
EmadedinMLabibzadehNLiastaniMG, et al.
Intra-articular implantation of autologous bone marrow-derived mesenchymal stromal cells to treat knee osteoarthritis: a randomized, triple-blind, placebo-controlled phase 1/2 clinical trial. Cytotherapy. 2018,
20: 1238–46.
33.
FiceMPMillerJCChristianR, et al.
The role of platelet-rich plasma in cartilage pathology: an updated systematic review of the basic science evidence. Arthroscopy. 2019,
35: 961–976.e3.
34.
FroumSJWallaceSSTarnowDPChoS-C.Effect of platelet-rich plasma on bone growth and osseointegration in human maxillary sinus grafts: three bilateral case reports. Int J Periodontics Restorative Dent. 2002,
22: 45–53.
35.
GargNKGaurSSharmaS.Percutaneous autogenous bone marrow grafting in 20 cases of ununited fracture. Acta Orthop Scand. 1993,
64: 671–2.
36.
GhannamSPèneJMoquet-TorcyGJorgensenCYsselH.Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol. 2010,
185: 302–12.
37.
GiannottiSTrombiLBottaiV, et al.
Use of autologous human mesenchymal stromal cell/fibrin clot constructs in upper limb non-unions: long-term assessment. PLoS One. 2013,
8: e73893.
HealeyJHZimmermanPAMcDonnellJMLaneJM.Percutaneous bone marrow grafting of delayed union and nonunion in cancer patients. Clin Orthop Relat Res. 1990: 280–5.
40.
HernigouPPoignardABeaujeanFRouardH.Percutaneous autologous bone-marrow grafting for nonunions. Influence of the number and concentration of progenitor cells. J Bone Joint Surg Am. 2005,
87: 1430–7.
41.
HernigouPHommaYFlouzat-LachanietteC-HPoignardAChevallierNRouardH.Cancer risk is not increased in patients treated for orthopaedic diseases with autologous bone marrow cell concentrate. J Bone Joint Surg Am. 2013,
95: 2215–21.
42.
HunterDJPikeMCJonasBLKissinEKropJMcAlindonT.Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis. BMC Musculoskelet Disord. 2010,
11: 232.
43.
IkonenJLähdeojaTArdernCLBuchbinderRReitoAKarjalainenT.Persistent tennis elbow symptoms have little prognostic value: a systematic review and meta-analysis. Clin Orthop Relat Res. 2022,
480: 647–60.
44.
JamesAWLaChaudGShenJ, et al.
A review of the clinical side effects of bone morphogenetic protein-2. Tissue Eng Part B Rev. 2016,
22: 284–97.
45.
JanjuaFAHasanONaqviFAMadhaniSUmerM.An audit of the effect of bone morphogenetic protein-2 treatment in patients with non-union of long bone fractures. J Pak Med Assoc. 2022,
72: 1401–5.
46.
JärvinenTA.Neovascularisation in tendinopathy: from eradication to stabilisation?Br J Sports Med. 2020,
54: 1–2.
47.
JoCHLeeYGShinWH, et al.
Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof-of-concept clinical trial. Stem Cells. 2014,
32: 1254–66.
48.
KarjalainenTVSilagyMO’BryanEJohnstonRVCyrilSBuchbinderR.Autologous blood and platelet-rich plasma injection therapy for lateral elbow pain. Cochrane Database Syst Rev. 2021,
9: CD010951.
49.
KaspirisAHadjimichaelACVasiliadisESPapachristouDJGiannoudisPVPanagiotopoulosEC.Therapeutic efficacy and safety of osteoinductive factors and cellular therapies for long bone fractures and non-unions: a meta-analysis and systematic review. J Clin Med. 2022,
11: 3901.
KesslerETakaharaKBiniaminovLBruselMGreenspanDS.Bone morphogenetic protein-1: the type i procollagen C-proteinase. Science. 1996,
271: 360–2.
52.
KimK-ILeeMCLeeJH, et al.
Clinical efficacy and safety of the intra-articular injection of autologous adipose-derived mesenchymal stem cells for knee osteoarthritis: a phase III, randomized, double-blind, placebo-controlled trial. Am J Sports Med. 2023,
51: 2243–53.
53.
KimSang JunKimEKKimSun JeongSongDH.Effects of bone marrow aspirate concentrate and platelet-rich plasma on patients with partial tear of the rotator cuff tendon. J Orthop Surg Res. 2018,
13: 1.
54.
KitohHKitakojiTTsuchiyaH, et al.
Transplantation of marrow-derived mesenchymal stem cells and platelet-rich plasma during distraction osteogenesis–a preliminary result of three cases. Bone. 2004,
35: 892–8.
55.
LaPradeRFDragooJLKohJLMurrayIRGeeslinAGChuCR.AAOS research symposium updates and consensus: biologic treatment of orthopaedic injuries. J Am Acad Orthop Surg. 2016,
24: e62–78.
56.
LeeSYKimWLimCChungSG.Treatment of lateral epicondylosis by using allogeneic adipose-derived mesenchymal stem cells: a pilot study. Stem Cells. 2015,
33: 2995–3005.
57.
LewisEMerghaniKRobertsonI, et al.
The effectiveness of leucocyte-poor platelet-rich plasma injections on symptomatic early osteoarthritis of the knee: the PEAK randomized controlled trial. Bone Joint J. 2022,
104-B: 663–71.
58.
LoweryGLKulkarniSPennisiAE.Use of autologous growth factors in lumbar spinal fusion. Bone. 1999,
25: 47S–50S.
59.
MalahiasM-ARoumeliotisLNikolaouVSChronopoulosESourlasIBabisGC.Platelet-rich plasma versus corticosteroid intra-articular injections for the treatment of trapeziometacarpal arthritis: a prospective randomized controlled clinical trial. Cartilage. 2021,
12: 51–61.
60.
MalhotraRKumarVGargB, et al.
Role of autologous platelet-rich plasma in treatment of long-bone nonunions: a prospective study. Musculoskelet Surg. 2015,
99: 243–8.
61.
MarcacciMKonEMoukhachevV, et al.
Stem cells associated with macroporous bioceramics for long bone repair: 6- to 7-year outcome of a pilot clinical study. Tissue Eng. 2007,
13: 947–55.
62.
Mardani-KiviMLeiliEKEsnaashariSHashemi-MotlaghKAzariZ.Relationship between the underlying factors and the treatment results of platelet-rich plasma (PRP) injection in degenerative knee disease; a blinded randomized study. Asian J Sports Med. 2023,
14.
63.
MarxRECarlsonEREichstaedtRMSchimmeleSRStraussJEGeorgeffKR.Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998,
85: 638–46.
64.
MatthewsSJE.Biological activity of bone morphogenetic proteins (BMP’s). Injury. 2005,
36: S34–7.
65.
MautnerKGottschalkMBodenSD, et al.
Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat Med. 2023,
29: 3120–6.
66.
NamaziHMehbudiA.Investigating the effect of intra-articular PRP injection on pain and function improvement in patients with distal radius fracture. Orthop Traumatol Surg Res. 2016,
102: 47–52.
67.
Nunes-TamashiroJCNatourJRamuthFM, et al.
Intra-articular injection with platelet-rich plasma compared to triamcinolone hexacetonide or saline solution in knee osteoarthritis: A double blinded randomized controlled trial with one year follow-up. Clin Rehabil. 2022,
36: 900–15.
68.
ObanaKKSchallmoMSHongIS, et al.
Current trends in orthobiologics: an 11-year review of the orthopaedic literature. Am J Sports Med. 2022,
50: 3121–9.
69.
PolmearMMAndersonABLanierPJOrrJDNestiLJDunnJC.Bone morphogenetic protein in scaphoid nonunion: a systematic review. J Wrist Surg. 2021,
10: 184–9.
70.
PountosIGeorgouliTHenshawKBirdHJonesEGiannoudisPV.The effect of bone morphogenetic protein-2, bone morphogenetic protein-7, parathyroid hormone, and platelet-derived growth factor on the proliferation and osteogenic differentiation of mesenchymal stem cells derived from osteoporotic bone. J Orthop Trauma. 2010,
24: 552–6.
71.
QamarAMohsinSNSiddiquiUNNazSDanishS.Effectiveness of platelet rich plasma for the management of knee osteoarthritis. PJMHS. 2021,
15: 1553–6.
72.
RhodesLVAntoonJWMuirSEElliottSBeckmanBSBurowME.Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk. Mol Cancer. 2010,
9: 295.
73.
SadriBHassanzadehMBagherifardA, et al.
Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial. Stem Cell Res Ther. 2023,
14: 162.
74.
SandlerABScanaliatoJPRaiciulescuSNestiLDunnJC.Bone morphogenic protein for upper extremity fractures: a systematic review. Hand (NY). 2023,
18: 80–8.
75.
SarafAHussainABishnoiSAzamGHabibH.Serial platelet-rich plasma intra-articular injections in Kellgren and Lawrence grade IV knee joint osteoarthritis: a prospective blinded placebo-controlled interventional study. Indian J Orthop. 2022,
56: 1722–8.
76.
ShapiroSAKazmerchakSEHeckmanMGZubairACO’ConnorMI.A prospective, single-blind, placebo-controlled trial of bone marrow aspirate concentrate for knee osteoarthritis. Am J Sports Med. 2017,
45: 82–90.
77.
SinghAKShettySSaraswathyJJSinhaA.Percutaneous autologous bone marrow injections for delayed or non-union of bones. J Orthop Surg (Hong Kong). 2013,
21: 60–4.
78.
SuzukiKSunROriguchiM, et al.
Mesenchymal stromal cells promote tumor growth through the enhancement of neovascularization. Mol Med. 2011,
17: 579–87.
79.
TaralloLMugnaiRAdaniRCataniF.Treatment of the ulna non-unions using dynamic compression plate fixation, iliac bone grafting and autologous platelet concentrate. Eur J Orthoped Surg Traumatol. 2012,
22: 681–7.
80.
ToroGLeporeFCalabròG, et al.
Humeral shaft non-union in the elderly: results with cortical graft plus stem cells. Injury. 2019,
50 Suppl 2: S75–9.
81.
TsaiK-SYangS-HLeiY-P, et al.
Mesenchymal stem cells promote formation of colorectal tumors in mice. Gastroenterology. 2011,
141: 1046–56.
82.
UristMR.Bone: formation by autoinduction. Science. 1965,
150: 893–9.
83.
ViswanathanSShiYGalipeauJ, et al.
Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell Committee position statement on nomenclature. Cytotherapy. 2019,
21: 1019–24.
84.
WakitaniSOkabeTHoribeS, et al.
Safety of autologous bone marrow-derived mesenchymal stem cell transplantation for cartilage repair in 41 patients with 45 joints followed for up to 11 years and 5 months. Journal of Tissue Engineering and Regenerative Medicine. 2011,
5: 146–50.
85.
WangRNGreenJWangZ, et al.
Bone morphogenetic protein (BMP) signaling in development and human diseases. Genes Dis. 2014,
1: 87–105.
86.
WangXChuWZhuangY, et al.
Bone mesenchymal stem cell-enriched β-tricalcium phosphate scaffold processed by the screen-enrich-combine circulating system promotes regeneration of diaphyseal bone non-union. Cell Transplant. 2019,
28: 212–23.
87.
WinterRTucaAJustichI, et al.
Minimally Invasive treatment of trapeziometacarpal osteoarthritis: results of a blinded randomized controlled trial. Plastic Reconstruct Surg. 2023,
152: 1277–85.
88.
WongJMurphyMWuYFMurphyRFruehFSFarneboS.Basic science approaches to common hand surgery problems. J Hand Surg (Eur).2022,
47: 117–26.
89.
YeLLewis-RussellJMKyanastonHGJiangWG.Bone morphogenetic proteins and their receptor signaling in prostate cancer. Histol Histopathol. 2007,
22: 1129–47.
